Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Providing a vast range of custom biologic services, including plasmid DNA production, mRNA production and antibody development, Aldevron is helping companies worldwide lay the foundations for groundbreaking science and discoveries.
Based on its unique Enable enFuse technology, Enable Injections is developing body-worn small devices that enable patients to self-administer high-viscosity drugs conveniently throughout the day upon activation.
Cryoport’s experience in cold chain logistics is now facing its biggest challenge yet—keeping patients’ therapies safe from damage in the revolutionary new field of cell therapy.
This technology is directed towards a potential treatment for a new disease, CHAPLE (Complement Hyperactivation, Angiopathic thrombosis, and Protein-Losing Enteropathy), identified by NIAID researchers. CHAPLE is associated with GI symptoms and vascular thrombosis and is caused by loss-of-function variants in the gene encoding the complement regulatory protein CD55. Recent off-label use of a complement inhibiting drug, eculizumab (CD55 inhibitor) was shown to provide a dramatic benefit in patients with CHAPLE disease with an immediate correction of gastrointestinal protein loss. Thus, identification of CD55 deficiency in CHAPLE patients, and the possibility to use complement inhibitory drugs provide opportunities for treatment.
The present invention provides a reverse genetics system encoding strain B1 of RSV subgroup B containing a codon-optimized G ORF and encoding eGFP. This provides a tool for RSV subgroup B serology assays, for tracking RSV infection, and a starting point for making attenuated subgroup B strains for vaccine purposes.
Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases created immunogenic PIV fusion (F) glycoproteins for types 1,2,3 and 4 (hPIV1, hPIV2, hPIV3 and hPIV4) that have been modified to stabilize the prefusion conformation. These stabilized prefusion F immunogens, especially hPIV3, induced high titer neutralizing responses in mice and rhesus macaques, and should thus serve as promising candidates for the prevention of PIV infection in humans.
Multiple sclerosis (MS) is an autoimmune disease caused by activated autoimmune T lymphocytes in patients resulting in inflammatory demyelination in the central nervous system. A specific therapy aimed at eliminating these autoimmune T cells through restimulation-induced cell death (RICD) could cure the disease and overcome the fatal side effects of current therapies. NIAID inventors have identified a multi-valent tolerogen (MMPt), which can specifically elicit RICD of the activated, disease causing autoimmune T cells without compromising the general T cell-dependent immunity in the host. Animal studies have demonstrated that MMPt exerts robust therapeutic effects on both monophasic as well as relapsing-remitting type of the disease, indicating its medical applicability for treating MS patients with active disease.
The NIH/NIAID has developed recombinant human parainfluenza virus type 1 (rHPIV1) bearing a stabilized attenuating mutation in the P/C gene to express the membrane-anchored form of Ebola virus glycoprotein GP as an intranasal (IN) Ebola virus vaccine.
NIAID researchers have discovered that blocking CD300f function in dendritic cells markedly enhances their ability to phagocytose and process apoptotic tumor cells, leading to substantial inhibition of tumor growth. Inhibiting CD300f function on dendritic cells could be a promising anti-cancer therapy, especially in the settings where blocking of T cell checkpoint receptors has been ineffective.
Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases introduced multiple N-linked glycosylation sites to mask non- conserved CD4-binding site regions of eOD-GT8 60mer to focus the antibody immune response to the CD4bs. Due to their improved antigenic and immunogenic profiles, glycan-masked eOD-GT8 60mer mutants may serve as improved priming immunogens to elicit VRC01-class broadly neutralizing antibodies in humans.
M3 Biotechnology is advancing a novel, potentially transformative approach for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Unlike other products approved and in development, M3’s drug candidates hold the potential to reverse or halt the degenerative process.
Unlike standard analgesics, the company’s lead compound ricolinostat is a disease-modifying therapy that reverses nerve damage and reduces pain, numbness, and muscle weakness resulting from diabetes, chemotherapy, and Charcot–Marie–Tooth disease.
Researchers at the Vaccine Research Center (“VRC”) have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation. The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response.
Researchers at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) have designed influenza vaccine candidates based on group 2 influenza hemagglutinin (HA) proteins. These group 2 HA proteins were engineered to remove the highly variable head region and stabilize the remaining stem region. The researchers then fused the engineered group 2 HA stabilized stem with a ferritin subunit. These immunogens elicit cross-reactive antibodies to group 2 influenza viruses and could be used in combination with group 1 HA stem-ferritin immunogens as a universal influenza vaccine.
Researchers at the VRC/NIAID have stabilized the conformation of the Env trimer of HIV-1 so that it displays the epitopes known to elicit broadly neutralizing antibodies. This stabilized Env trimer is termed BGSOSIP505 and is useful as an HIV vaccine candidate.
NIAID scientists have discovered that Rostafuroxin, a synthetic digitoxigenin derivative, inhibits RSV infection in respiratory epithelial cells by inhibiting the RSV induced ATP1A1-mediated signaling pathway required for RSV entry. Rostafuroxin is a promising anti-viral drug candidate for RSV and possibly other viruses that use the same pathway for host cell entry.
Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases are developing novel recombinant ferritin nanoparticles that are based on insect ferritin proteins, and that have been engineered to display two different trimeric antigens in a defined ratio and geometric pattern. An animal study demonstrated that after immunization with ferritin nanoparticles displaying two different trimeric antigens induced B cells could simultaneously recognize both trimeric antigens, thus leading to an immune response with improved neutralization breadth.
This probe set can capture and enrich influenza viral sequences selectively and effectively in a variety of samples, such as clinical samples with degraded nucleotides or samples containing very low amounts of influenza virus, thus making it a valuable tool for influenza virus diagnoses and surveillance.
This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays.
